Given the recent availability of antiretroviral therapy (ART) in resource-limited settings and the significant burden exacted by Kaposi's sarcoma in these areas, we reviewed data regarding the impact of ART on Kaposi's sarcoma incidence. We summarized the sizeable literature in resource-rich settings as well as emerging data from resource-limited regions. Importantly, we delineated ways impact can be defined, including individual patient-level effectiveness; population-level effectiveness; change in population-level incidence; and residual risk of Kaposi's sarcoma.
INTRODUCTION
The advent of HIV/AIDS in 1981 transformed Kaposi's sarcoma from a medical oddity to an epidemic [1] . In resource-rich settings, the cumulative lifetime incidence of Kaposi's sarcoma among HIV-infected homosexual men reached nearly 40% [2] . In many resource-limited settings, particularly sub-Saharan Africa, the extent of the HIV epidemic resulted in Kaposi's sarcoma becoming the most common malignancy not just among HIV-infected individuals but among all adults [3] . Yet, just as abruptly as AIDS impacted Kaposi's sarcoma, the advent of potent antiretroviral therapy (ART) has transformed HIV disease. In resource-rich areas where ART is routinely available, the lifespan of HIV-infected individuals has nearly normalized [4] . ART has come more slowly to resource-limited settings, but by the end of 2010 over 5 million patients in sub-Saharan Africa alone had initiated ART [5] with overall reduction in mortality comparable to resource-rich settings [6] .
Whereas the general impact of ART on morbidity and mortality has been well documented, this review will summarize the specific influence of ART on Kaposi's sarcoma incidence. We shall summarize the abundant data from resource-rich settings and (1) Question 1. What is the individual patient-level efficacy of ART on Kaposi's sarcoma incidence? This is akin to the question which would be addressed in a randomized trial of ART versus no ART in selected HIV-infected patients with optimal adherence. It asks: what is the best effect on Kaposi's sarcoma incidence that could be expected among ART users? Although interesting, such a trial has never been conducted because it is now unethical, and the question has never been addressed with observational data. Hence, we will not summarize literature for this question. (2) Question 2. What is the individual patient-level effectiveness of ART use on Kaposi's sarcoma incidence? This is akin to the question in a randomized trial of ART versus no ART in 'real world' clinical practice, which allows variable ART adherence and other circumstances. Such a randomized trial also cannot be ethically performed today, but several observational studies have attempted to estimate this effect.
(3) Question 3. What is the population-level effectiveness of ART on Kaposi's sarcoma incidence? This is what would be addressed in a randomized trial of 'real world' communities of HIVinfected individuals comparing availability of ART in a community versus no availability. This question incorporates the answer to question 2 above (individual patient-level effectiveness), but it extends upon it by encompassing the act of starting therapy. In other words, population-level effectiveness is a function of starting ART, adhering to ART, and the inherent efficacy of ART. (4) Question 4. How has Kaposi's sarcoma incidence among HIV-infected persons changed since the availability of ART? Although the randomized trial that addresses this question can be stated -what is the effect on Kaposi's sarcoma incidence if one is randomized to live in the pre-ART era (up to 1996) versus the era when ART is available (after 1996)? -it has no basis in reality. Yet, the question is relevant from a public health and population perspective in that it asks how Kaposi's sarcoma incidence has changed among all HIV-infected individuals since ART has become available. Whereas question 3 asks specifically whether ART per se is responsible for a change in Kaposi's sarcoma incidence among the HIV-infected population (independent of other factors), question 4 simply asks whether Kaposi's sarcoma incidence has changed since ART became available regardless of why. (5) Question 5. What is the residual risk of Kaposi's sarcoma given ART? This asks whether ART among HIV-infected patients, either in terms of use at the individual patient level or availability at the population level, reduces Kaposi's sarcoma incidence to that seen in HIV-uninfected individuals. It addresses the ultimate goal of ART in HIV-infected patients as it relates to Kaposi's sarcoma, which is to preclude any excess risk.
In reviewing the impact of ART on Kaposi's sarcoma incidence, we focused on the last four questions, namely individual patient-level effectiveness, population-level effectiveness, change in Kaposi's sarcoma incidence in the ART era, and residual risk.
METHODS
We reviewed published literature from 1996 to 2012, searching Medline and the Web of Science, which described the impact of ART on Kaposi's
KEY POINTS
There are abundant data from resource-rich settings indicating the beneficial effect of ART on preventing Kaposi's sarcoma, both among antiretroviral therapy (ART) users and within the entire HIV-infected population.
Methodological shortcomings of published studies in resource-rich settings, however, preclude our understanding of the actual magnitude of ART impact on Kaposi's sarcoma incidence and hence whether there is need for additional interventions apart from ART to reduce incidence.
Emerging data from resource-limited countries preliminarily suggest a beneficial impact of ART on Kaposi's sarcoma incidence comparable to that seen in resource-rich settings, but -considering the magnitude of Kaposi's sarcoma in resource-limited settings -much more data are needed to confirm the individual patientlevel effectiveness, determine population-level effectiveness, and establish residual risk of Kaposi's sarcoma given ART use.
In both resource-rich and resource-limited settings, more precise specific estimates of the incidence of Kaposi's sarcoma in ART-treated patients who have achieved CD4 cell counts greater than 350 cells/ml are needed.
RESOURCE-RICH SETTINGS
We discuss the impact of ART on Kaposi's sarcoma incidence in terms of individual patient-level and population-level effectiveness.
Individual patient-level effectiveness
With variable findings (Table 1) , nine studies [7] [8] [9] [10] [11] 12 && ,13,14,15 && ] across three continents have evaluated individual patient-level effectiveness of ART on Kaposi's sarcoma incidence (question 2). The lowest Kaposi's sarcoma incidence among ART users was 109 per 100 000 person-years [8] , whereas the highest incidence was 700 per 100 000 person-years [13] . Of special interest is the absolute Kaposi's sarcoma incidence among ART users who have achieved a CD4þ T-cell count of at least 350 cells/ml. This is important because the majority of ART users will spend the rest of their lives in this immunological state, and some notable case series have suggested that Kaposi's sarcoma may continue to be common in this range [19, 20] . Unfortunately, few studies provide formal estimates of Kaposi's sarcoma incidence among such patients. Among individuals with a CD4 cell count of at least 350 cells/ml, Franceschi et al. [9] and Lodi et al. [12 && ] reported incidences of 118 and 368 per 100 000 person-years, respectively. A lower incidence (89 per 100 000 person-years) was reported among ART users with CD4 cell count at least 500 cells/ml [12 && ]. After adjustment (in some studies) for various confounding factors, the Kaposi's sarcoma incidences among ART users represented declines between 19 and 93% compared with non-ART users ( Table 1) . Studies from Europe had a range between 61 and 93% [7] [8] [9] [10] [11] 12 && ,13], a 57% decline was observed in a multicountry study in Europe, Australia and Canada [12 && ], whereas a 19-39% reduction was seen in the US [14,15 && ]. The substantial variability between studies could have several explanations. First, the populations differed. For instance, Mocroft et al. [13] performed their work between 1994 and 1998, a period when ART users were heavily treatmentexperienced and likely enriched for those unable to achieve full virologic suppression on combination ART regimens compared with patients who started ART in later years. This could in part explain the smaller 61% reduction in Kaposi's sarcoma incidence that was found compared with other European estimates. Second, although rarely reported, ART impact also depends on compliance. For example, there was a seven-fold increase in Kaposi's sarcoma risk in the CD4 cell count-guided episodic ART arm of the Strategies for Management of Antiretroviral Therapy trial [21] . Third, the magnitude of losses to follow-up was also rarely reported, leaving open the possibility of selection bias. Whereas some studies [8] [9] [10] [11] were less susceptible, the potential for differential losses to follow-up between ART users and nonusers is uninterpretable in others [7,12 && ,13]. Fourth, with few exceptions [8] , the mode of Kaposi's sarcoma diagnosis was not reported. Although biopsy was surely performed in many instances, we also know that clinical diagnosis alone was common in some areas. The nonspecificity of clinical diagnosis will typically attenuate the apparent effect of ART.
As all available studies are observational, confounding could be another reason for variability. Whereas some studies reported adjusted estimates [7,11,14,15 && ], others were either unadjusted [8,9,12 && ,13] or adjustment was not reported [10, 14] . Notably, only two studies controlled for CD4 cell count [11, 14] , which would be expected to be a strong confounder. Yet, CD4 cell count in this context is also a time-dependent mediator of the effect of ART, which, if adjusted for conventionally, could attenuate the effect of ART. To manage confounding of this type, advanced approaches known as marginal structural models have emerged in the past decade [22] . Because none of the studies used these advanced techniques, we may qualitatively know the individual patient-level effectiveness of ART on Kaposi's sarcoma incidence but are yet to have an unbiased quantitative estimate.
In the one study that estimated residual Kaposi's sarcoma risk (question 5) at the individual patient level, ART users had a 25.3-fold higher rate of Kaposi's sarcoma compared with the general population [8] (Table 2 ). This study, however, used contemporaneous rates of Kaposi's sarcoma from the general population, which, because virtually all Kaposi's sarcoma in the general population today is derived from HIV-infected patients, tends to underestimate the parameter of interest (a comparison of ART-treated/HIV-infected persons with HIV-uninfected persons) [27] . On the contrary, any comparison (in most resource-rich settings) of HIV-infected persons to the general population (irrespective of era) that does not consider differences in the underlying prevalence of infection with Kaposi's sarcoma-associated herpesvirus (KSHV) will overestimate the residual risk of Kaposi's sarcoma in the HIV-infected group.
Population-level effects
Population-level impact of ART on Kaposi's sarcoma incidence has been evaluated by nine studies, all of which used regional/national cancer registries to ascertain incidence (Tables 3 and 4 ). In these studies, calendar time was the predictor variable, with pre-ART era (before 1996) compared with ART era (after 1996). Whether or not authors adjusted for one or more factors dictated the question they could address. Estimating population-level effectiveness of ART on Kaposi's sarcoma incidence (question 3) requires adjustment for whatever factors differ across calendar time. Population-level effectiveness was estimated by five studies [15 && ,25 && ,26 && ,28,29 & ], which found reductions between 33 and 95% in Kaposi's sarcoma incidence in the ART era ( Table 3) . Given that estimating the change in 28] . Second, there again may be differences in Kaposi's sarcoma ascertainment. Even though cancer registries were used to ascertain Kaposi's sarcoma, most studies insufficiently described the registries' processes. Differences across studies in the fraction of clinical Kaposi's sarcoma diagnoses, which are prone to nonspecificity, could contribute to the differences in the derived inferences. Finally, in the studies addressing population-level effectiveness of ART, in which differences across eras have to be addressed, there was disparity in how this was handled. For example, one study adjusted for ART use over and above calendar period, which, because it is on the causal pathway, would be expected to attenuate effects [15 && ]. Notably, no study accounted for CD4 cell count. Therefore, we again conclude that, although we know the qualitative population-level effectiveness of ART on Kaposi's sarcoma incidence, we do not have an accurate quantitative estimate.
Residual Kaposi's sarcoma risk in the ART era was assessed in three populations [23, 24, 25 && ,26 && ] ( Table 2) , with standardized incidence ratios ranging from 22.9 [25 && ] to 3640 [24] . Differences in composition of the general population comparator groups across studies likely explain this wide range. Specifically, the highest estimates used a general population group from the late 1970s that predated the HIV epidemic [24, 26 && ], and the lowest used the contemporary general population [25 && ]. As mentioned earlier, because almost all Kaposi's sarcoma that occurs in contemporary resource-rich general populations (outside the Mediterranean) is derived from HIV-infected persons, underestimation of the true residual risk among HIV-infected persons will result if this contemporaneous comparison group is used [27] .
Nonpopulation-based cohorts
A number of nonpopulation-based cohorts [14,33,34,35 & , [36] [37] [38] [39] [40] [41] [42] , typically clinic-derived, also compared incidence of Kaposi's sarcoma in both the pre-ART and ART eras (Table 5 ). However, when viewed from the perspective of the questions we initially outlined, these studies are not directly estimating any parameter of clinical or epidemiologic relevance (which is unfortunate because many of these studies have the best measurements). In a clinic-based cohort, the populationlevel effectiveness of ART will be overestimated. This is because the patients analyzed in the ART era are systematically enriched for those in care and are devoid of patients not on ART. Likewise, these studies are not validly estimating individual patient-level effectiveness because ART use per se was not the predictor variable. Indeed, many patients in these studies in the ART era were not actually using ART, thus leading to likely underestimation of the individual patient-level effectiveness of ART. It is therefore in the realm of individual patient-level effectiveness of ART that these nonpopulation-based cohort studies have their greatest contribution. Given that most are estimating above 70% reduction in Kaposi's sarcoma incidence, we can infer that the true value is likely in this range. 
RESOURCE-LIMITED SETTINGS
Despite having the vast majority of the worldwide HIV/AIDS and Kaposi's sarcoma burden, resourcelimited settings have yielded substantially less data regarding the impact of ART on Kaposi's sarcoma. It is nonetheless useful to consider the data in terms of individual patient-level and population-level effectiveness.
Individual patient-level effectiveness
In the one published study on this question, Kaposi's sarcoma incidence among ART users in Uganda was 340 cases per 100 000 person-years [16 && ] (Table 1 ). This study did not have a comparator group of non-ART users, but it can, in theory, be compared with historical work in the country. In 1988-2002 (a period with minimal ART availability), Mbulaiteye et al. [43] reported a Kaposi's sarcoma incidence of 380 per 100 000 person-years among HIV-infected patients in Kampala. This would seem to indicate no effectiveness of ART, but differences in Kaposi's sarcoma ascertainment between studies likely preclude any valid comparison. The recent work was in the context of a clinical trial in which patients were being prospectively examined. In contrast, the older work originated in a clinic population in which Kaposi's sarcoma diagnoses may have been easily missed and, furthermore, to be counted by the study, a Kaposi's sarcoma diagnosis had to be captured in a local cancer registry and matched back to the patient's clinic record. This likely resulted in substantial underestimation of Kaposi's sarcoma incidence in the pre-ART study, a limitation noted by the authors [43] .
More recent data, presented to date in abstract form only, promise to better estimate individual patient-level effectiveness. In the East Africa Consortium of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Project [44] , 98 024 HIV-infected adults at 26 HIV clinics in Uganda and Kenya were followed for incident Kaposi's sarcoma [18] . A unique feature of the work was that histological diagnosis was made available at the participating sites and accounted for approximately 50% of Kaposi's sarcoma diagnoses. In Uganda, Kaposi's sarcoma incidence was 1876 per 100 000 personyears in non-ART users and 201 in ART users, translating to a 78% reduction in Kaposi's sarcoma incidence [18] . In Kenya, Kaposi's sarcoma incidence was 596 per 100 000 person-years in non-ART users and 270 users in ART users, translating to a 50% reduction [18] . Another abstract, from Southern Africa IeDEA, covering 10 clinic-based cohorts with 184 592 patients, reported an incidence of 624 per 100 000 person-years among non-ART users and 174 per 100 000 person years in ART users, translating to a 72% reduction [17] . What accounts for the clinically important differences in ART effectiveness in Kenya versus Uganda (or South Africa) remains unclear given the unpublished nature of the work. Of note, in neither of these analyses was the role of CD4 cell count as a time-dependent confounder/mediator appropriately managed, again leaving us without a valid quantitative estimate of ART effect. ]. However, with the majority of Kaposi's sarcoma diagnoses being clinical (only 18% histopathologic), this study highlights the challenges of using registries to estimate population-level effects in resource-limited settings. These challenges also include issues with completeness [45] and unknown HIV status among the cases [46] . As such, we view the findings from these nominally populationbased studies as generally uninterpretable, and we therefore have no evaluable population-level data as it relates to Kaposi's sarcoma.
Population-level effects

CONCLUSION
There is now ample evidence to indicate substantial effectiveness of ART on Kaposi's sarcoma incidence at the individual patient level and population level in resource-rich settings. Although in preliminary form, there is now emerging evidence to also suggest that the individual patient-level effectiveness of ART on Kaposi's sarcoma incidence in resource-limited settings is comparable to that in resource-rich settings. Yet, considering the public health magnitude of Kaposi's sarcoma in resource-limited settings, particularly in sub-Saharan Africa, much more data from diverse settings are needed to confirm the individual patient-level effectiveness observed in the initial studies, determine population-level effectiveness, and establish residual risk of Kaposi's sarcoma given ART use. From a methodological perspective, whereas we can safely qualitatively conclude that ART works in preventing Kaposi's sarcoma, the actual magnitude of the effect has never been properly estimated due to the improper handling of time-dependent confounding/mediation. Not knowing the actual magnitude of the ART effect is more than just academic, in that it will inform whether additional interventions (e.g. anti-KSHV agents) are needed in combination with ART in order to more fully reduce Kaposi's sarcoma incidence. This is critical, since evaluating additional interventions will be very expensive. Finally, to understand the face of HIV-associated Kaposi's sarcoma in the future, we need additional specific estimates of the incidence of Kaposi's sarcoma in ART-treated patients who have achieved CD4 cell counts above 350 cells/ml, as well as an understanding of why patients continue to develop Kaposi's sarcoma at this stage of HIV disease.
